Assessing the pharmacokinetics of Ampicillin in newborns' umbilical cord blood and plasma after intrapartum administration for preventing early onset group B streptococcal infection (A prospective study).

The purpose of this study is to determine whether or not ampicillin, following a standard prophylactic dose against group B streptococcal infection, reaches concentrations above the minimum inhibitory concentrations (MIC) in maternal plasma and umbilical cord blood (UCB). From January 2024 to December 2024, this prospective study was conducted at Al-Azhar and Helwan University Hospitals and included 200 newborns whose moms had received intrapartum ampicillin. There were 200 maternal plasma samples and 200 UCB samples available for examination (between 5 and 75 minutes postpartum). As fast as five minutes after ampicillin infusion, the mean ampicillin concentrations found in maternal and umbilical cord sera all surpassed the lowest bactericidal values documented for group B streptococci (0.25 to 2.0 micrograms/ml). Neonatal quantities of ampicillin over the MIC of GBS are the result of intrapartum dosing.